HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

Trastuzumab is effective in the treatment of HER2/neu over-expressing breast cancer, but not all patients benefit from it. In vitro data suggest a role for HER3 in the initiation of signaling activity involving the AKT–mTOR pathway leading to trastuzumab insensitivity. We sought to investigate the p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Lipton, Allan, Goodman, Laurie, Leitzel, Kim, Cook, Jennifer, Sperinde, Jeff, Haddad, Mojgan, Köstler, Wolfgang J., Huang, Weidong, Weidler, Jodi M., Ali, Suhail, Newton, Alicia, Fuchs, Eva-Marie, Paquet, Agnes, Singer, Christian F., Horvat, Reinhard, Jin, Xueguang, Banerjee, Joyee, Mukherjee, Ali, Tan, Yuping, Shi, Yining, Chenna, Ahmed, Larson, Jeff, Lie, Yolanda, Sherwood, Thomas, Petropoulos, Christos J., Williams, Stephen, Winslow, John, Parry, Gordon, Bates, Michael
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2013
Konular:
Preclinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3758835/
https://ncbi.nlm.nih.gov/pubmed/23959396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2665-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller